Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23274047 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1CHRM3AGTR2KEAP1 | |
| SCHEMBL4047414 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1CHRM3AGTR2KEAP1 | |
| SCHEMBL23415469 | 0.98 | CHRM2 (0.37) | CHRM2CHRM1CHRM3AGTR2KEAP1 | |
| SCHEMBL23415565 | 0.98 | CHRM2 (0.37) | CHRM2CHRM1CHRM3AGTR2KEAP1 | |
| SCHEMBL23415467 | 0.98 | CHRM2 (0.37) | CHRM2CHRM1CHRM3AGTR2KEAP1 | |
| SCHEMBL16498041 | 0.86 | KIF11 (0.42) | NOTUMALDH1A1SMN1; SMN2 | |
| SCHEMBL3825923 | 0.85 | CHRM3 (0.36) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| SCHEMBL25897057 | 0.85 | CHRM3 (0.36) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| SCHEMBL3825928 | 0.85 | MAPT (0.40) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| SCHEMBL5234612 | 0.84 | S1PR1 (0.39) | NOTUMALDH1A1SLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461315-B1 | CATALYTIC CARBONYLATION OF THREE AND FOUR MEMBERED HETEROCYCLES | CORNELL RES FOUNDATION INC (US) | 2009-07-29 | — | — | EP | claimed |
| EP-4048671-B1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | AMGEN INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4684786-A2 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | LEIDOS BIOMEDICAL RESEARCH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| CN-115873020-B | RAS inhibitors | 锐新医药公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12252497-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| EP-1461315-B1 | CATALYTIC CARBONYLATION OF THREE AND FOUR MEMBERED HETEROCYCLES | CORNELL RES FOUNDATION INC (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| EP-1985624-A2 | Single step method of radiofluorination of biologically active compounds or biomolecules | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008083729-A1 | RADIOLABELLING VIA FLUORINATION OF AZIRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-17 | — | — | WO | disclosed |
| EP-1944288-A1 | Radiolabelling via fluorination of aziridines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944288-A1 | Radiolabelling via fluorination of aziridines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-6852865-B2 | Catalytic carbonylation of three and four membered heterocycles | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030162961-A1 | Catalytic carbonylation of three and four membered heterocycles | CORNELL RESEARCH FOUNDATION, INC. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051306-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4885/4885CHRM1 4884/4885CHRM3 4874/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | CHRM2 4876/4885CHRM1 4864/4885CHRM3 4877/4885 |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | CHRM2 4759/4885CHRM1 4666/4885CHRM3 4813/4885 |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | TMEM14C, ARFGEF1, NPFFR1 | CHRM2 1990/4885CHRM1 1307/4885CHRM3 1654/4885 |
| US-12252497-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CHRM2 4885/4885CHRM1 4884/4885CHRM3 4879/4885 |
| US-20030162961-A1 | Catalytic carbonylation of three and four membered heterocycles | LOX, CA9, LPO | CHRM2 294/4885CHRM1 115/4885CHRM3 668/4885 |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | KRAS, NRAS, HRAS | CHRM2 3912/4885CHRM1 3585/4885CHRM3 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.